Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMDA glycine-site agents to enhance iTBS antidepressant efficacy
ChiCTR2500095767Phase 2Recruiting
- Sponsor
- Linyi Mental Health Center
- Start
- Jan 2025
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of d-cycloserine, d-serine and l-leucine in major depressive disorder (MDD) (4 arms), sponsored by Linyi Mental Health Center. Primary endpoint: Depression level. Started Jan 2025; status: recruiting.
02
Drugs
d-cycloserined-serinel-leucine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2500095767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095767.